Wayne State University researchers received a two-year, $140,000 award from the U.S. Department of Defense to target esophageal cancer cell defenses.
Led by Dr. Husain Yar Khan, assistant professor in the Department of Oncology in the Wayne State University School of Medicine, the project investigates how to trigger a specialized form of cell death called ferroptosis. The funding arrives through the Rare Cancers Research Program Concept Award mechanism. Joining Khan as co-investigators are Department of Oncology faculty members Dr. Asfar Azmi and Dr. Yang Shi.
Esophageal cancer presents primarily as esophageal squamous cell carcinoma or esophageal adenocarcinoma. The malignancy carries a poor prognosis, particularly at advanced stages, and patients frequently experience disease recurrence despite intensive surgery, radiation, and chemotherapy.
The project, titled “Inducing Ferroptosis Through GPX4 Inhibition as a Novel Therapeutic Approach for Esophageal Cancer,” examines a cell death process distinct from traditional treatments. Cancer cells rely on antioxidant defenses, specifically the enzyme GPX4, to prevent the buildup of damaging oxidized lipids in cell membranes.
Khan’s team will test the experimental compound ML210 to inhibit GPX4.
This mechanism aims to overwhelm cancer cell defenses and induce ferroptosis in tumors that resist standard therapies.
“Esophageal cancer remains an urgent clinical challenge because existing therapies too often fail to prevent recurrence,” Khan said. “By focusing on GPX4 inhibition, our goal is to investigate a potentially important biological vulnerability that could complement existing treatment strategies.”
Targeting Military Populations and Rare Malignancies
While classified as a rare cancer, the disease represents an unmet medical need for veterans and military-connected populations. Developing effective therapeutic approaches aims to improve survival rates and long-term quality of life for patients within the military community and beyond.
The research team will evaluate GPX4 inhibition using laboratory models of both major forms of esophageal cancer. They will also test patient-derived tumor models that reflect human disease biology, while investigating biological markers of ferroptosis and treatment response.
The preclinical study establishes foundational proof-of-concept data for future translational development. The findings could also provide a framework for treating other rare cancers that depend on identical antioxidant defense machinery.
“This research exemplifies Wayne State’s commitment to high-impact discovery that addresses pressing clinical challenges and unmet medical needs,” Dr. Ezemenari M. Obasi, vice president for research & innovation at Wayne State University, said.
The Office of the Assistant Secretary of Defense for Health Affairs supports the work under award number HT9425261E381.
Researchers Test ML210 Compound on Esophageal Cancer
What specific compound are the researchers testing to inhibit cancer defenses?
The research team will test the experimental compound ML210 to inhibit the GPX4 enzyme in esophageal cancer cell models.
Which specific grant program funded this esophageal cancer project?
The Department of Defense funded the project through its Rare Cancers Research Program Concept Award mechanism, providing a two-year, $140,000 award.
Who are the co-investigators collaborating on the Wayne State study?
Dr. Asfar Azmi, professor in the Department of Oncology, and Dr. Yang Shi, assistant professor in the Department of Oncology, are serving as co-investigators alongside lead researcher Dr. Husain Yar Khan.
Keep reading